HURN Huron Consulting Group Inc.

Huron Announces Senior Leadership Transitions

Global professional services firm Huron (NASDAQ: HURN) today announced Gordon J. Mountford will step down as leader of the healthcare practice, and John D. Kelly has been promoted to Executive Vice President and Chief Financial Officer.

In connection with the change in practice leadership, C. Mark Hussey, Huron’s Executive Vice President and Chief Operating Officer, has been named interim leader of the healthcare practice, effective immediately, while the company initiates a search for a new leader. Hussey will also retain his responsibilities as COO.

“Gordon has made significant contributions to Huron, including building Huron’s healthcare business from its infancy to the market leader it is today. With our proven ability to deliver measurable results, the practice has become the transformation partner for our clients as we address their most pressing strategic, organizational and operational challenges,” said James H. Roth, chief executive officer and president, Huron. “We thank Gordon for his tremendous service to the firm and wish him the best in the future.”

“Mark is a trusted leader within Huron with a deep understanding of our business and is well respected by our people, making him the ideal candidate to lead the healthcare practice during this transition,” added Roth. “We are aggressively recruiting and remain fully committed to advancing the strategic priorities that will return the healthcare practice to growth.”

In addition, the company announced the promotion of John D. Kelly to Executive Vice President and Chief Financial Officer, reporting to Roth, effective immediately. Kelly, a 10-year veteran of the company, previously served as Corporate Vice President, Chief Accounting Officer and Treasurer. In his new role, Kelly will assume global responsibility for corporate finance, accounting, treasury, and capital and financing strategies. He will retain his position as Treasurer.

“John is a talented executive and has built a strong reputation within the company and within our investor community,” said Roth. “The Huron board and I are confident that John’s experience and deep knowledge of our business will be instrumental as we execute our financial strategy to further position the company for growth.”

Kelly has held a variety of roles at Huron since he joined the firm in 2006. He served as Treasurer and Chief Accounting Officer of Huron since his appointments in 2016 and 2015, respectively. Prior to his role as Chief Accounting Officer, Kelly served as Controller and Assistant Controller. Prior to joining the Corporate team, he was a Director in Huron’s Disputes and Investigations practice. Kelly joined Huron from Deloitte & Touche, where he held several positions on the Assurance and Advisory Services team.

ABOUT HURON

Huron is a global professional services firm committed to achieving sustainable results in partnership with its clients. The company brings depth of expertise in strategy, technology, operations, advisory services and analytics to drive lasting and measurable results in the healthcare, higher education, life sciences and commercial sectors. Through focus, passion and collaboration, Huron provides guidance to support organizations as they contend with the change transforming their industries and businesses. Learn more at www.huronconsultinggroup.com.

EN
06/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Huron Consulting Group Inc.

Anish Jog ... (+4)
  • Anish Jog
  • Daniel Ives
  • Sam Brandeis
  • Steven Wahrhaftig

Solid Results with Strength Across All Business Segments; Navigating M...

A Closer Look at FY3Q25 (September) ResultsRevenueTotal revenue before reimbursable expenses (RBR) of $432.4 million (up 17% y/y) came in above the Street’s $420.0 million estimate reflecting growth across all three verticals including 10% organic growth.Healthcare revenue came in at $219.5 million

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Anish Jog ... (+4)
  • Anish Jog
  • Daniel Ives
  • Sam Brandeis
  • Steven Wahrhaftig

Solid Results with Raised Guidance; Capitalizing Across All Segments

A Closer Look at FY2Q25 (June) ResultsRevenueTotal revenue before reimbursable expenses (RBR) of $402.5 million (up 8% y/y) came in slightly below the Street’s $402.6 billion estimate reflecting strength in digital capabilities in commercial and education along with consulting and managed services

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch